Relay Therapeutics, Inc. (NasdaqGM: RLAY)
Health Care · Biotechnology · US
$17.92
+0.22% today · +163.7% 1Y
Relay Therapeutics, Inc. (NasdaqGM: RLAY) operates in the Biotechnology industry within the Health Care sector. The company is valued at $3.92B and employs 202 people.
Over the last twelve months the share price has gained 163.7%, trading between 5.85 and 21.27.
Tweenvest scores Relay Therapeutics, Inc. across four factors: quality 37/100, value 69/100, growth 0/100. Its strongest factor is value.
RLAY price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $3.92B
- Revenue (TTM)
- $10.35M
- P/E
- —
- EPS
- -1.57
- Dividend yield
- —
- Beta (5Y)
- 1.73
- 52-week high
- $21.27
- 52-week low
- $5.85
- Avg volume (3M)
- —
- Shares outstanding
- 219.14M
- Employees
- 202
- Next earnings
- —
About Relay Therapeutics, Inc.
Relay Therapeutics, Inc. is a precision medicine company currently engaged in clinical trials. Its central mission involves revolutionizing the drug discovery process, with a particular focus on enhancing the creation of small molecule therapies for specific types of cancer and genetic conditions. The company's pipeline features several promising drug candidates: RLY-4008, an orally administered small molecule designed to inhibit fibroblast growth factor receptor 2 (FGFR2), which is undergoing its initial human trials for patients with advanced or metastatic solid tumors exhibiting FGFR2 alterations; RLY-2608, a leading program targeting mutant phosphoinositide 3 kinase alpha (PI3Ka); and RLY-1971, another oral small molecule, an inhibitor of SHP2 (protein tyrosine phosphatase Src homology region 2 domain-containing phosphatase-2), currently in Phase 1 trials for individuals with advanced solid tumors. Relay Therapeutics has established strategic partnerships, including a collaboration with D. E. Shaw Research, LLC, which utilizes computational modeling to analyze protein motion for the identification and development of therapeutic compounds. Furthermore, an agreement with Genentech, Inc. supports the development and commercialization of RLY-1971. Founded in 2015 as Allostery, Inc., the company rebranded to Relay Therapeutics, Inc. in December of that year and maintains its headquarters in Cambridge, Massachusetts.
- ISIN
- US75943R1023
- Founded
- 2015
- Listed since
- Jul 16, 2020
- Exchange
- Nasdaq Global Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Imeik Technology Development Co.,Ltd.SZSE: 300896 | $4.28B | CN¥95.03 | -0.16% |
| Dizal (Jiangsu) Pharmaceutical Co., Ltd.SHSE: 688192 | $4.16B | CN¥59.95 | +3.34% |
| Suzhou Zelgen Biopharmaceuticals Co., Ltd.SHSE: 688266 | $4.12B | CN¥104.25 | -5.23% |
| Tango Therapeutics, Inc.NasdaqGM: TNGX | $4.01B | $24.17 | +1.51% |
| Telix Pharmaceuticals LimitedASX: TLX | $3.76B | AU$15.85 | -0.13% |
| Beijing Tiantan Biological Products Co., Ltd.SHSE: 600161 | $3.76B | CN¥12.73 | +1.11% |
| Hualan Biological Engineering Inc.SZSE: 002007 | $3.64B | CN¥13.35 | +0.07% |
| Veracyte, Inc.NasdaqGM: VCYT | $3.64B | $43.53 | -3.76% |
Figures last refreshed Oct 11, 2026.